Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
* Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG) * Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback * Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP) * Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with Jans...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 6) * 9 Meters Biopharma Inc (NASDAQ: NMTR) * AngioDynamics, Inc. (NASDAQ: ANGO) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * BIO-TECHNE Corp (NASDAQ: TECH) * Endo International PLC (NASDAQ: ENDP) * Eyenovia Inc (NASDAQ: EYEN) * Fulgent Genetics Inc (NAS...
* Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year * Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China * argenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other payments Regulated Information/Inside InformationBreda, the Netherlands, Shanghai and San Francis...
January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET.A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A re...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]
The $39 billion transaction brings a franchise in rare immune disorders to Astra, while ending a campaign by discontented Alexion stockholders to get the company sold.
November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the company has agreed to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals, Inc for $98 million. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biolo...